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CC BY-NC-ND license (http://creativeAbstract Many cancers have similar aberrations in various signaling cascades with crucial
roles in cellular proliferation, differentiation, and morphogenesis. Dysregulation of signal cas-
cades that play integral roles during early cellular development is well known to be a central
feature of many malignancies. One such signaling cascade is the Wnt/b-catenin pathway,
which has a profound effect on stem cell proliferation, migration, and differentiation. This
pathway is dysregulated in numerous cell types, underscoring its global oncogenetic potential.
This review highlights regulators and downstream effectors of this receptor cascade and ad-
dresses the increasingly apparent crosstalk of Wnt with other tumorigenic signaling pathways.
As understanding of the genetic and epigenetic changes unique to these malignancies in-
creases, identifying the regulatory mechanisms unique to the Wnt/b-catenin pathway and
similarly aberrant receptor pathways will be imperative.
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Wnt signaling plays a central role in cell proliferation, dif-
ferentiation, and morphogenesis.1e3 It is a critical step in b-
catenin signal transduction and is responsible for main-
taining its own unphosphorylated state. In its dephos-
phorylated state, b-catenin is localized in the nucleus,
where it activates transcription factors in the T-cell factor
(TCF)/lymphoid enhancing factor (LEF) family.4e6 In the
absence of Wnt activity, b-catenin is phosphorylated byand hosting by Elsevier B.V. This is an open access article under the
4.0/).
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quent degradation by the Skp, Cullin, F-box containing
complex (SCF)/ubiquitin/proteasome pathway.7e12 In its
active, dephosphorylated state, b-catenin has a profound
effect on the regulation of stem cells.13,14 Researchers have
illustrated this with mammary stem cells in both native and
ectopic locations.15e18 When the Wnt pathway is upregu-
lated, it consistently results in tumorigenesis in a variety of
organs.19e21
In particular, aberrant activation of b-catenineTCF/LEF
signals secondary to adenomatous polyposis coli, axin, and
b-catenin gain-of-function mutations are associated with
the development of colon cancer, desmoid tumors, gastric
cancer, hepatocellular carcinoma, medulloblastoma, mel-
anoma, ovarian cancer, pancreatic cancer, and prostate
cancer.19e21 Studies have demonstrated that these muta-
tions are not the sole sources of b-catenin hyperactivity,
however. For instance, Ashihara et al22 demonstrated nu-
clear accumulation of b-catenin in 60% of their endometrial
tumor specimens. However, the CTNNB1 gene, which en-
codes b-catenin, was mutated in only 10% of the specimens.
Investigators have found similar results in studies of mela-
noma, hepatocellular carcinoma, and glioma in which
CTNNB1 and GSK-3b expression were largely normal in
respective cancer cell lines.23e28 A potential explanation
for this phenomenon is the presence of additional pathways
mediating the nuclear translocation of b-catenin. Increased
epidermal growth factor and AKT-dependent b-catenin
phosphorylation is associated with increased b-catenin nu-
clear localization.29,30 Members of our laboratory have
demonstrated that Forkhead box M1 (FoxM1), which is a
downstream component of the Wnt signaling pathway,
binds to cytosolic b-catenin and the two factors subse-
quently undergo nuclear translocation in glioma cells.31
Wnt signaling has a crucial role in neural development.
Both in vitro and in vivo studies have demonstrated the
necessity of Wnt signaling for neural stem cell (NSC)
renewal and differentiation.32 These findings were corrob-
orated by a study using adult hippocampal progenitor cells
in which b-catenin upregulation promoted hippocampal
enlargement, whereas its downregulation led to small
hippocampi.33 Researchers have obtained similar findings
for gain-of-function and loss-of-function mutations of b-
catenin. Specifically, gain-of-function mutations increased
NSC proliferation in the periventricular zone, causing brain
enlargement, whereas loss-of-function mutations caused
marked brain shrinkage.34Positive regulators of Wnt/b-catenin signaling
Dishevelled and Frizzled 4 proteins promote nuclear
localization of b-catenin
Various factors have been attributed to the dedifferenti-
ating capacity of Wnt signaling. For instance, the scaffold
protein, Dishevelled is activated by the Wnt pathway. The
Dishevelled-Axin domain mediates the effects of the ca-
nonical Wnt pathway, which signals subsequent binding to
Axin for disassembly of b-catenin from its destruction
complex.35 Glioblastoma (GBM) cells deficient in Dishev-
elled 2 exhibited unchecked proliferation.36 Similarly, Wnt
activation of the transmembrane protein Frizzled 4 (FZD4)can promotes nuclear translocation of b-catenin when
overexpressed, whereas nuclear levels of it decrease when
its gene is not present.37
PLAGL2 contributes to a b-catenin-mediated
undifferentiated state in NSCs
PLAGL2 is a zinc-finger protein localized to the nucleus that
has been demonstrated to upregulate expression of Wnt
pathway receptors and its associated proteins in NSCs. In-
vestigators found that these PLAGL2 expressing NSCs were
maintained in an undifferentiated state and that b-catenin
expression was higher in the NSCs than in control cells.
Moreover, the Wnt-promoting effects of PLAGL2 and the
undifferentiated NSC state was reversible following trans-
fection with the Wnt inhibitor Dickkopf-1 into the cells.38
FoxM1 is a downstream component of Wnt signaling
Our laboratory personnel have contributed to elucidating
the role of FoxM1 in b-catenin signaling. FoxM1 is a tran-
scription factor with a pivotal role in glioma formation and
has been shown to be overexpressed in GBM cells.39,40
Using liquid chromatography-mass spectrometry, we
confirmed that FoxM1 interacted with b-catenin. In the
same study, we also revealed that FoxM1 and b-catenin
were co-localized in both the cytoplasm and nucleus using
various in vitro methods. Moreover, using Wnt3a-based
treatment, we demonstrated nuclear accumulation of
both FoxM1 and b-catenin in 293FT cells, which suggested
that FoxM1 is a downstream component of the Wnt
signaling pathway.31
FoxM1 tumorigenicity is b-catenin-dependent
We confirmed that FoxM1 promoted nuclear translocation
of b-catenin in glioma stem cells (GSCs) and showed that
GSCs with knockdown of both FoxM1 and b-catenin
expression had reduced numbers of neural colony-forming
units.31 Additionally, we found that FoxM1 markedly
increased the formation of b-catenineTCF/LEF transcrip-
tional complexes, as well as the expression of its gene
products Axin2, LEF-1, c-Myc, and cyclin D1. In another
experiment, we found that FoxM1 overexpression main-
tained the undifferentiated state of GSCs and promoted
neurosphere formation.31 To clarify the downstream role of
b-catenin in FoxM1-mediated tumorigenicity, we investi-
gated b-catenin knockdown in GSCs overexpressing FoxM1.
We found that the combination of b-catenin knockdown in
lieu on FoxM1 overexpression still decreased tumor forma-
tion in mice. However, we observed increased tumor bur-
dens in mice lacking b-catenin knockdown but possessing
GSCs with FoxM1 overexpression.
We corroborated the finding that b-catenin and FoxM1
are overexpressed and colocalized to the nucleus in human
GBM specimens. We proved that FoxM1 expression corre-
lated directly with nuclear b-catenin expression. In addi-
tion, we showed that the expression of the stem cell
marker nestin and the Wnt targets Axin2 and LEF-1 were
elevated in direct correlation with FoxM1 expression.
Finally, immunofluorescent staining of GBM specimens
validated nuclear co-localization of b-catenin and FoxM1
and demonstrated increased Nestin and decreased glial
fibrillary acidic protein staining in FoxM1-positive GBM
specimens.31 These findings demonstrated that the
FoxM1 and Wnt/b-catenin in glioma and other cancers 43tumorigenicity of FoxM1 is b-catenin-mediated and that
FoxM1 expression promotes the undifferentiated state of
stem cells.Negative regulators of Wnt/b-catenin signaling
Paternally expressed gene 3 prevents Wnt activity via
p53-mediated degradation
Paternally expressed gene 3 has been demonstrated to
impair zebrafish embryogenesis by preventing Wnt-
dependent tail development.41,42 In addition, the absence
of paternally expressed gene 3 expression was associated
with increased glioma formation, whereas its over-
expression resulted in decreased glioma tumorigenicity.43
This paternally expressed gene 3-mediated inhibition of
Wnt activity was found to be secondary to increased pro-
teasomal degradation of b-catenin independent of GSK-3b.
Similar to other studies demonstrating p53-mediated
degradation of b-catenin, Jiang and colleagues showed
that p53-associated decreases in b-catenin expression were
lost with knockout of Siah1.42 Furthermore, this group
demonstrated that paternally expressed gene 3 knockdown
is associated with increased b-catenin expression and that
paternally expressed gene 3 expression inversely correlates
glioma grade.42,43
Wnt activation can be blocked by inhibiting its
interactions with lipoprotein receptor-related protein 5
and 6 and FZD4
Dickkopf-1 (DKK1) is a well-described inhibitor of canonical
Wnt activity in humans and has been demonstrated to have
proapoptotic effects and increased expression in various
human cancer cell lines.44 DKK1 is a glycoprotein that binds
to lipoprotein receptor-related protein 5 (LRP5) and LRP6
and the membrane protein Kremen, which promote endo-
cytosis of the DKK1-LRP5/6-Kremen complex. This prevents
the formation of a Wnt-LRP5/6-FZD4 complex that would
activate the canonical pathway.45 This effect has not been
shown to decrease glioma tumorigenicity. On the other
hand, inactivation of secreted FZD-related protein has been
shown to be correlated with the development of various
malignancies, including glioma.47 Secreted FZD-related
protein is a homolog of the FZD receptors that binds to
extracellular Wnt and prevents it from interacting with li-
gands linked with b-catenin activation.48-49 This was
confirmed in in vitro and in vivo studies that demonstrated
decreased b-catenin expression, reduced GSC viability, and
decreased tumorigenicity in mice. Additionally, authors
have reported that secreted FZD-related protein is a che-
mosensitizing agent.37,50,51
a2-Macroglobulin/LRP1 binding downregulates Wnt
activity
a2-Macroglobulin has been shown to suppress tumor inva-
sion after binding to LRP1, which subsequently marks
transforming growth factor-b, as well as various proteases
involved in extracellular matrix destruction for
endocytosis-related inactivation.52,53 Linder et al found
that the b-catenin-stabilizing effects of LiCl could be
reversed by a2-macroglobulin administration in 1321N1 as-
trocytoma cells. Furthermore, LRP1 binding upregulated b-catenin, LRP1, E-cadherin, N-cadherin, and FZD expression
while downregulating Wnt1, Wnt5a, and Wnt10b expression
in 1321N1 cells.54 These results were reproduced when
using a polyclonal anti-LRP1 antibody to stimulate the a2-
macroglobulin receptor in 1321N1 cells.
YAP/TAZ-Axin1 interaction marks b-catenin for
destruction
A central feature of b-catenin’s ultimate fate is its inter-
action with the scaffold protein Axin1, which directs its
subsequent interaction with other cytoplasmic proteins,
such as GSK-3b, adenomatous polyposis coli, and casein
kinase-1. GSK-3b-mediated presentation of b-catenin to
the ubiquitin ligase b-transducin repeat-containing protein
is an important step in b-catenin destruction.55 In Wnt-off
HEK293 cells, which contain a functioning b-catenin
destruction complex, Azzolin et al showed that Axin1
possesses high levels of co-precipitation with b-catenin,
GSK-3b, b-transducin repeat-containing protein, YAP, and
TAZ.56 Furthermore, Axin1/2 knockdown did not result in
YAP/TAZ accumulation HEK293 cell with destruction
complex components. This knockdown resulted in
increased nuclear accumulation of YAP and TAZ, as well as
increased transcriptional activity of the YAP/TAZ target
gene CTGF.56
Similarly, treatment of HEK293 cells with Wnt3a resulted
in nuclear localization of both YAP and TAZ, as well as
upregulated expression of other YAP/TAZ target genes. In
addition, this treatment decreased the association of YAP
and TAZ with the destruction complex. Immunoprecipita-
tion of these Wnt-treated cells demonstrated interaction
with the LRP6 protein instead, suggesting that Wnt signaling
inhibits b-catenin destruction by preventing YAP/TAZ
interaction with the destruction complex. This was
confirmed by loss of detectable co-precipitation of YAP and
TAZ with destruction complex proteins in cells transfected
with LRP6 gene-containing plasmids. Finally, Azzolin et al
showed that the ubiquitin ligase b-transducin repeat-
containing protein interacted with the destruction com-
plex in both Wnt3a- and LRP6-treated cells, but this inter-
action was extinguished with increasing YAP expression in
Wnt-on cells.56Downstream effects of Wnt signaling
Wnt stimulation inhibits the mammalian target of
rapamycin pathway of tuberous sclerosis complex 2 via a
GSK-3beAMP-activated protein kinase-dependent
cascade
The canonical Wnt pathway has numerous downstream ef-
fects following its interaction with the TCF/LEF family of
transcription factors. These effects are largely secondary
to cyclin D1 and c-Myc activation.4,57 The pathway vastly
influences many other signal cascades attributed to de-
rangements in cellular differentiation and growth. For
example, the tuberous sclerosis complex 2 pathway is
dependent on phosphorylation by various kinases, such as
AMP-activated protein kinase (AMPK) for downstream ac-
tivity. Wnt3a-treated cells have been shown to increase the
phosphorylation of S6K, 4EBP1, and S6, which are markers
of mammalian target of rapamycin (mTOR) function. These
44 S.-A.L. Morris, S. Huangeffects were lost following administration of mTOR phos-
phorylation inhibitors, indicating that the effects of Wnt in
part are mediated by this pathway.
In addition, mice overexpressing Wnt10b had marked
enlargement of calvarial tissue, as well as increased phos-
phorylation of S6.58 S6 phosphorylation decreased when
rapamycin, an mTOR inhibitor was administered to mice
bearing mammary tumor cells overexpressing Wnt1. Simi-
larly, mice with knockdown of LRP1 receptor expression
had smaller than normal calvarias. Furthermore, investi-
gation of Wnt-expressing hyperplastic mammary tissue and
mammary tumor cells revealed elevated mTOR activity that
could be reversed following rapamycin treatment, which
also reduced the size of both cell types.
These effects were not influenced by b-catenin activity,
as underexpression of both b-catenin and TCFs had no ef-
fect on S6 phosphorylation. However, in GSK-3b expressing
HEK293 cells there was decreased S6 phosphorylation, and
administration of the GSK-3b inhibitors LiCl and GSKi in
HEK293 and mouse embryonic fibroblast cells increased S6
phosphorylation levels. This was an effect of the interde-
pendence of AMPK and GSK-3b activities. When AMPK ac-
tivators were introduced into Wnt-treated cells, S6
phosphorylation decreased. On the other hand, adminis-
tration of LiCl diminished the mTOR-blocking ability of
AMPK activators. Likewise, AMPK inhibition negated the
inhibitory effects of GSK-3b in the HEK293 cell line.58
Pygopus 2 mediates the downstream effects of Wnt
involved in Notch signaling crosstalk
Wnt signaling has been shown to increase the maintenance
of mammary stem cells in their undifferentiated state,
whereas Notch signaling promotes the differentiation of
these stem cells into a luminal cell type.15e18,59e61 With
this in mind, deletions of Pygopus 2 (Pygo2), which is a
known transcriptional co-factor with Wnt signaling, has
been demonstrated to impair mammary morphogenesis.62
Pygo2-deficient mammary stem cells were shown to
differentiate into more mature luminal/alveolar variants.
These cells had upregulated expression of Notch signaling
components, Notch3, Dll4, and Hes1. In another experi-
ment, Wnt signaling was upregulated by treatment with a
GSK-3b inhibitor or cloning of a stabilized b-catenin, both of
which decreased luminal/alveolar differentiation. This ef-
fect was lost in cells with Pygo2 knockdown. Moreover,
micro chromatin immunoprecipitation assays revealed that
both b-catenin and Pygo2 had high affinity for the Notch3
locus as well as the Axin2 locus. Furthermore, b-catenin
binding mammary stem cells was markedly reduced in
Pygo2’s absence, suggesting that Pygo2 is a key co-activator
of Wnt signaling’s downstream effects and in its crosstalk
with the Notch pathway.63
Wnt signaling has repressive effects on Sonic hedgehog
signaling
Sonic hedgehog (SHH) has a critical role in embryogenesis
and is responsible for morphogenesis of neural structures as
well as the proliferation of granule neuron precursors in the
cerebellum.64,65 In its active state, SHH binds to Patch re-
ceptors and increases the activity of Smoothened re-
ceptors, thus allowing the transcription of glioma-
associated oncogenes homologs (Gli1/2/3).66 Whendysregulated the SHH pathway can promote gastric cancer,
medulloblastoma, skin cancer, and GBM formation. Despite
an association of both Wnt and SHH overexpression with a
propensity for tumor development, Wnt activity can impair
SHH-mediated tumorigenesis.67e71
Nuclear staining for b-catenin was shown to be increased
in poorly differentiated gastric adenocarcinomas (60%),
whereas nuclear staining for Gli1 was decreased in these
tumors (30%).67 The inverse was observed in well-
differentiated adenocarcinomas with respect to nuclear
staining for Gli2 (100%) and b-catenin (70%). This was
confirmed following treatment with NaBU, an agent that
promotes cellular differentiation, which did not change
levels of cytoplasmic b-catenin but decreased b-catenin
nuclear expression in AGS and MKN-45 cells. These gastric
cancer cells were later treated with a Gli-overexpressing
vector or NaBU, both of which increased expression of the
Wnt antagonist secreted FZD-related protein 1. This effect
was lost following introduction of a Gli antagonist into the
cells. Finally, chromatin immunoprecipitation verified that
both Gli and secreted FZD-related protein 1 are bound b-
catenin during its suppression.66
Wnt10b and nuclear b-catenin expression levels in the
keratinocytes of skin tumor placodes in mice were
measured and compared with the levels in fully developed
skin tumors.70 The keratinocytes had higher levels of the
Wnt signaling components than did the tumors. In contrast,
Patch1, Patch2, and Gli1 expression increased in the kera-
tinocytes of the skin tumor placodes as the researches
progressed from normal to skin tumor regions in mice. To
clarify the roles of Wnt and SHH in tumor initiation and
growth, the Wnt inhibitor exisulind (Aptosyn) and SHH in-
hibitor cyclopamine were injected into separate groups of
mice. In comparison with transgenic mice, Aptosyn-treated
animals had markedly lower new hair follicle growth and
lower nuclear b-catenin levels expression. In comparison,
cyclopamine-treated mice had no changes in the degree of
new follicle outgrowth but did have substantially lower
tumor growth than did the transgenic group.70
Similar findings were demonstrated by Po¨schl et al.68 In
their study, the proliferation of granule neuron precursors
with upregulation of Smoothened 2 activity was 2.6-fold
higher than that of wild-type granule neuron precursors.
Conversely, CTNNB expression reduced the proliferative
capacity, as well as cellular proliferation in the granule
neuron precursors with increased Smoothened 2 expression
to near-wild-type levels. These results were reproduced in
mice, which had much smaller cerebellums and cerebellar
tumors when the Smoothened 2 and CTNNB genes were co-
expressed than when Smoothened 2 was expressed alone.
Further experimentation confirmed that both Axin2 and b-
catenin expression were increased but Gli1 expression was
decreased in mice with upregulation of expression of both
genes, supporting Wnt-mediated inhibition of SHH
signaling.68
In another study of the effects of Wnt signaling on SHH
activity in medulloblastoma cells, LiCl administration
caused an expected rise in nuclear b-catenin expression as
well as decreased Patch2 and Gli1 expression.69 This could
be only partly reversed by proteasome inhibition, suggest-
ing that another Wnt-dependent mechanism contributed to
decreased Gli1 activity. Of note, many more
FoxM1 and Wnt/b-catenin in glioma and other cancers 45medulloblastoma cells were in a nonproliferative state
following LiCl treatment as opposed to cells treated with
NaCl. This was demonstrated by decreased Ki-67 and
phosphor-histone H3 staining and increased senescence-
associated nuclear b-galactosidase immunopositivity
following LiCl treatment. Immunoprecipitation assays
verified both nuclear and cytoplasmic co-precipitation of
the two factors in LiCl-treated cells but not in control cells.
In addition, the researchers observed that Gli1 knockdown
did not inhibit Wnt signaling. Finally, mice injected with
Patch-expressing medulloblastoma cells had markedly
longer tumor formation intervals than did control mice
when administered LiCl.68
Much more investigation must be done to clarify the role
of Wnt/SHH crosstalk in GBM cells. Previous studies
demonstrated a role for SHH in promoting migration of
glioma cells.72 In addition, gene network analysis demon-
strated expression trends linking Wnt and SHH signaling
through the Gli2 transcription factor. This connection links
the destruction complex components, GSK-3b and casein
kinase-1-a1 with the Wnt and SHH pathways, as bothFigure 1 The figure demonstrates the wide array of interactions
catenin phosphorylation by the GSK-3/APC/YAP-TAZ destruction c
mediated phosphorylation of its targets, S6, S6K, and 4EBP1. Onc
location to promote transcription of its various target genes. On
decrease the transcription of the Notch pathway target genes. E
phosphorylation; on the other hand, PEG3 can facilitate p53-me
stream, both Wnt and Sonic Hedgehog signaling decrease Gli 2/3 a
subsequent a2-macroglobulin activity decrease the expression of Welements have roles in the inactivation of downstream
signals.71 Although the mechanisms of interplay between
Wnt and SHH signaling remain unclear, the modes of
crosstalk may be similar to those in previous gastric cancer,
skin cancer, and medulloblastoma studies.Conclusions and future directions
Wnt signaling has a far-reaching influence with respect to
its involvement in cellular differentiation and tumor initi-
ation and progression. Many of its roles involve the inter-
play of separate signaling cascades. Fig. 1 illustrates the
various regulators and downstream effectors of the Wnt
pathway discussed in this review. Of interest are the roles
of Wnt and SHH expression in various stages of glioma
progression, as both pathways are associated with
increased tumor invasiveness owing to upregulation of
metalloproteinase activity.73,74 However, SHH-mediated
invasiveness cancer cell lines has been demonstrated only
when Gli1 mutations have resulted in truncation of the Gli1present in the Wnt signaling cascade. Wnt signaling prevents b-
omplex. In addition, Wnt has been shown to promote mTOR-
e associated with FoxM1, b-catenin undergoes nuclear trans-
e of the b-catenin target genes, Pygopus has been shown to
GFR signaling can inhibit b-catenin activity by AKT-mediated
diated proteasomal degradation of b-catenin. Further down-
nd Wnt expression, respectively. Similarly, LRP1 activation and
nt.
46 S.-A.L. Morris, S. Huangtranscription factor. Future studies are needed to identify
targets of these pathways that can safely modulate their
activity because of their integral roles in the normal pro-
cesses in cells with high mitotic activity, such as skin,
blood, and gut epithelial cells.Conflicts of interest
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